Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

Learn more about:
Related Clinical Trial
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule Optimising Molecular Radionuclide Therapy Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer Function Integrity of Neck Anatomy in Thyroid Surgery An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System Evaluation of a New CZT System Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Modified Cormack Lehane Scores Evaluated by Laryngoscopy During Awake Versus Under General Anesthesia Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain A Study Into the Effect of Seprafilm in Open Total Thyroidectomy Lenvatinib and Pembrolizumab in DTC Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Influence of Thyroid Hormones on the Woundhealing Process ctDNA in Patients With Thyroid Nodules Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine Trial of LBH589 in Metastatic Thyroid Cancer Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma Thyroid Cancer and Sunitinib Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients Lipid Metabolic Status in Thyroid Carcinoma

Brief Title

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

Official Title

Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements

Brief Summary

      This phase II trial is studying how well selumetinib works in treating patients with
      papillary thyroid cancer that did not respond to radioactive iodine. Selumetinib may stop the
      growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed Description


      I. Ascertain the objective response rate (complete response and partial response) in patients
      with iodine I 131-refractory papillary thyroid cancer treated with selumetinib.


      I. Determine the toxicity of this treatment in these patients. II. Determine the
      pharmacokinetic profile of this treatment in these patients. III. Determine the
      progression-free and overall survival of these patients. IV. Assess proxy measures of
      treatment response (thyroglobulin and PET scan) in patients treated with selumetinib.

      IV. Compare relevant laboratory correlates between responders and non-responders.

      OUTLINE: This is a multicenter study.

      Patients receive oral selumetinib twice daily on days 1-28. Treatment repeats every 28 days
      in the absence of unacceptable toxicity or disease progression.

      Archived tissue is examined for gene mutations, including RET, BRAF, NTRK, and RAS, by
      fluorescence in situ hybridization and/or polymerase chain reaction and fluorescence melting
      curve analysis. Protein expression of ERK and phosphorylated ERK is assessed by
      immunohistochemical staining.

      Blood samples are collected periodically for pharmacokinetic analysis and biomarker
      assessment (thyroglobulin and antithyroglobulin autoantibodies).

      After completion of study therapy, patients are followed periodically for up to 2 years.

Study Phase

Phase 2

Study Type


Primary Outcome

Objective Response Rate (ORR)

Secondary Outcome

 Median Progression-Free Survival (PFS)


Recurrent Thyroid Gland Carcinoma


Laboratory Biomarker Analysis

Study Arms / Comparison Groups

 Arm I
Description:  Patients receive oral selumetinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

December 2007

Completion Date

August 2016

Primary Completion Date

August 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically or cytologically confirmed papillary thyroid cancer or papillary
             thyroid cancer with follicular elements

          -  No longer amenable to radioactive iodine therapy or curative surgical resection

               -  Tumor is no longer iodine avid

               -  Tumor did not respond to the most recent radioactive iodine treatment

               -  Patient is ineligible for further radioactive iodine therapy due to medical
                  contraindications (e.g., lung toxicity)

          -  Measurable disease, defined as at least one lesion that can be accurately measured in
             at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional
             techniques or as ≥ 10 mm with spiral CT scan

          -  Evidence of disease progression (objective growth of existing tumors)

               -  New or enlarging measurable lesions within the past 12 months

               -  If the most recent imaging study is older than 12 months, patients will still be
                  eligible if objectively measurable disease progression is associated with
                  clinical symptoms

          -  Archival tumor tissue available for mutational analysis

          -  No known brain metastases

          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

          -  Life expectancy > 12 weeks

          -  WBC ≥ 3,000/µL

          -  ANC ≥ 1,500/µL

          -  Platelet count ≥ 100,000/µL

          -  Total bilirubin normal

          -  AST and ALT < 2.5 times upper limit of normal

          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception prior to, during, and for 4 weeks
             after completion of study treatment

          -  Able to understand and willing to sign a written informed consent document

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to selumetinib (AZD6244) or its excipient Captisol®

          -  QTc interval > 450 msec or other factors that increase the risk of QT prolongation

          -  Arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT
             interval syndrome), including heart failure that meets NYHA class III and IV

          -  Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory
             bowel disease), or significant bowel resection that would preclude adequate absorption

          -  Concurrent uncontrolled illness including, but not limited to, ongoing or active
             infection or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  At least 4 weeks since prior radiotherapy or chemotherapy (6 weeks for nitrosoureas or
             mitomycin C)

          -  Prior treatment with tyrosine kinase inhibitors that target RET or RAF

          -  Prior treatment with MEK inhibitors

          -  Concurrent combination antiretroviral therapy for HIV-positive patients

          -  Concurrent medication that can prolong the QT interval

          -  Other concurrent investigational agents




18 Years - N/A

Accepts Healthy Volunteers



David Neil Hayes, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

National Cancer Institute (NCI)

Study Sponsor

David Neil Hayes, Principal Investigator, UNC Lineberger Comprehensive Cancer Center

Verification Date

December 2016